Paeds SAQs · endocrinology-diabetes-and-growth
Growth hormone deficiency and excess — formative SAQs
Formative SAQs on recognising the short child with growth hormone deficiency and the overgrowing child with growth hormone excess, confirming with a stimulation test or an oral glucose load, and delivering recombinant growth hormone for deficiency and surgery with somatostatin analogue or pegvisomant for excess.
On this page & tools
Target exams
SAQ 1 (10 marks)
A 6-year-old boy is referred because he is the shortest in his class. His height is on the 0.4th centile, more than two standard deviations below the mid-parental target, his growth velocity over the past year has been 4 cm/year (subnormal for age), and his bone age is delayed by two years. His IGF-1 is low for age. [1] [3]
a) State the most likely endocrine diagnosis and justify it from the growth-chart and biochemical findings. (2 marks) [1] [3]
b) Outline the next investigations, including the stimulation test, its agent and its cutoff, and the imaging. (4 marks) [5] [1]
c) Describe the definitive therapy: drug, route, starting dose, and the monitoring that makes it safe. (4 marks) [1] [2]
Answer
a) Growth hormone deficiency (isolated, pending exclusion of multiple pituitary hormone deficiency). The height is below the third centile and distant from the mid-parental range, the growth velocity is subnormal for age, the bone age is delayed, and the IGF-1 is low — the biochemical and auxological signature of an endocrine growth failure rather than a constitutional variant. [1] [2]
b) Two growth hormone stimulation tests (clonidine and arginine, or glucagon), with a peak growth hormone below 6.7 to 10 ng/mL consistent with deficiency; pituitary magnetic resonance imaging to define the anatomy and exclude a structural lesion; and a full pituitary axis panel (TSH, free T4, cortisol, prolactin, gonadotrophins) to detect accompanying deficiencies. The cutoff was lowered from 10 to 6.7 ng/mL with modern immunoassays to improve specificity. [5] [1]
c) Recombinant human growth hormone, subcutaneous once daily at bedtime, starting at 0.045 to 0.050 mg/kg/day and titrated to keep the IGF-1 in the upper half of the age- and sex-normal range. Monitor growth velocity, IGF-1, adherence and injection sites at each visit, and screen for adverse effects — headache and papilloedema (benign intracranial hypertension), slipped capital femoral epiphysis, scoliosis, glucose intolerance — with annual thyroid function. [1] [2]
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References7Show ledgerHide ledger
- [1]Collett-Solberg PF, et al. Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society international perspective. Horm Res Paediatr, 2019.PMID 31514194
- [2]Grimberg A, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents. Horm Res Paediatr, 2016.PMID 27884013
- [3]Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child, 2016.PMID 26153506
- [5]Guzzetti C, et al. Cut-off limits of the peak GH response to stimulation tests for the diagnosis of GH deficiency in children and adolescents. Eur J Endocrinol, 2016.PMID 27147639
- [10]Korbonits M, et al. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases. Nat Rev Endocrinol, 2024.PMID 38336898
- [11]Joshi K, et al. Resistant paediatric somatotropinomas due to AIP mutations: role of pegvisomant. Horm Res Paediatr, 2018.PMID 29953972
- [12]Daly AF, et al. The genetic pathophysiology and clinical management of the TADopathy, X-linked acrogigantism. Endocr Rev, 2024.PMID 38696651